Search results

8 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
Located in Newsroom / UNC Lineberger in the News
UNC Lineberger team finds possible strategy to overcome radiation therapy resistance acquired by cancer cells
In a new study published in the Cell Press journal Chemistry & Biology, researchers share a discovery that they say could lead to a new strategy for sensitizing radiation-resistant cancer cells to the treatment.
Located in News
Researchers define structure, function of enzyme key to blood cancers
In the journal Nature, UNC Lineberger's Greg Wang, PhD, and colleagues reported findings about the structure and function of the DNMT3A enzyme complex, which helps control gene expression.
Located in News
Located in Newsroom / UNC Lineberger in the News
Former patient donates $10 million to further blood cancer research at UNC Lineberger
Etteinne “ET” and W. G. Champion “Champ” Mitchell of New Bern, North Carolina, will create a new fund supporting ground-breaking research in blood cancer at UNC Lineberger Comprehensive Cancer Center, including lymphoma, leukemia and myeloma research, in gratitude for the care Champ received and to bolster research directed at finding cures.
Located in News
‘The singing patient’ hopes his music will inspire others
Decorated military veteran MG Autry says service to others is central to his life. Even when he is facing his own health challenges, he would have it no other way.
Located in News
Researchers lay the foundation for personalized immune treatments for leukemia
In the journal Blood Advances, UNC Lineberger’s Ben Vincent, MD, Paul Armistead, MD, PhD, and their collaborators reported early findings from a new study that could aid in the development of immune-based treatments that are tailored to individual leukemia patients who are undergoing stem cell transplantation.
Located in News
Results 'encouraging' from phase II trial for relapsed acute myeloid leukemia
UNC Lineberger’s Joshua Zeidner, MD, reported preliminary data at the 60th American Society of Hematology Annual Meeting from a phase II clinical trial for administering a high-dose of the chemotherapy treatment cytarabine followed by an immune checkpoint inhibitor, pembrolizumab, in patients with acute myeloid leukemia that had relapsed or no longer responded to other treatment.
Located in News